Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran

Eastern Mediterranean Health Journal

Volumn 11, Issue 1-2, 2005, Pages 62-67

  Zali, M R ^a   Mohammad, K ^b   Noorbala, A A ^b   Noorimayer, B ^a   Sahraz, S ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT ANTIGEN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; CHILD; CHILD HEALTH CARE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; IMMUNOASSAY; IRAN; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; PREVENTIVE HEALTH SERVICE; SEROEPIDEMIOLOGY; SEX DIFFERENCE; URBAN RURAL DIFFERENCE; VIRUS CARRIER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CARRIER STATE; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH SERVICES RESEARCH; HEALTH SURVEYS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; IRAN; MALE; MASS IMMUNIZATION; MIDDLE AGED; POPULATION SURVEILLANCE; PROGRAM EVALUATION; RURAL HEALTH; SEROEPIDEMIOLOGIC STUDIES; URBAN HEALTH;

EID: 33644601728     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine, 1990, 8(Suppl.):S18-20.
2. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterology clinics of North America, 1994, 23:437-55.
3. Maynard JE, Kane MA, Hadler SC. Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Program on Immunization. Reviews of infectious diseases, 1989, 11(Suppl.3):S574-8.
4. Kane M. Global program for control of hepatitis B infection. Vaccine, 1995, 13(Suppl.1):S47-9.
5. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Seminars in liver disease, 1991, 11:84-92.
6. Hadler SC et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. New England journal of medicine, 1986, 315:209-14.
7. Margolis HS et al. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. Journal of the American Medical Association, 1995. 274:1201-8.
8. Toukan AU. Hepatitis B in the Middle East: aspects of epidemiology and liver disease after infection. Gut, 1996, 38(Suppl. 2):S2-4.
9. Poovorawan Y et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine, 2000, 19(7-8):943-9.
10. Viviani S, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine, 1999, 17(23-24):2946-50.
11. Coursaget P et al. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet, 1986, 2(8516):1143-5.
12. Rizzetto M, Zanetti AR. Progress in the prevention and control of viral hepatitis type B: closing remarks. Journal of medical virology, 2002, 67(3):463-6.
13. Merat S et al. Hepatitis B in Iran. Archives of Iranian medicine, 2000, 3(4):192-201.
14. Gardner MJ, Altman DG, eds. Statistics with confidence. London: British Medical Journal, 1989.
15. Kew MC. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut, 1996, 38(Suppl. 2):S31-6.
16. Al-Faleh FZ et al. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. Journal of infection, 1999, 38:167-70.
17. Chen HL et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. Journal of the American Medical Association, 1996, 276(22):1802-3.
18. Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine, 1990, 8(suppl.):S129-33, discussion S134-8.